Program context
BEYONDXLH was an Ultragenyx-sponsored disease monitoring program involving the XLH Network as co-sponsor and Yale as the centralized research site. Kevin’s career record places his work from January 2019 through December 2023. The program formed part of his early sponsor-side responsibility for longitudinal clinical research and patient self-reported data.
Kevin’s responsibilities
Kevin’s documented work includes study leadership, design enhancements, compliance oversight, procedure development, system testing, data analysis, data-loss prevention, and program improvements. His later responsibilities included mentoring the lead study manager. These roles combined program management with technology and data-quality judgment.
Working across internal stakeholders, research investigators, research associates, technology vendors, and patient-community organizations required a shared understanding of what participants were being asked to do and how that effort supported the research objective.
Patient and site experience
Longitudinal programs depend on participants being able to keep contributing information as their circumstances change. Kevin’s work emphasized patient-facing data capture, collaborative site workflows, and operational feedback. The systems had to fit participants’ lives while also supporting research procedures and data continuity.
The involvement of an advocacy organization and an academic research partner is significant: participant engagement, scientific requirements, and sponsor execution had to remain aligned. Kevin’s wider Ultragenyx work also included structured patient-community consultation under compliance oversight.
Connection to the Innovation Lab
Experience with these research requirements helped Kevin identify the value of a reusable internal clinical technology capability. His CV describes development of a strategic plan, early prototypes, and executive approval to establish the Innovation Lab. BEYONDXLH therefore connects direct study work with the later platform and organization-building story.
Rarify and the broader clinical technology portfolio expanded the ability to support patient and site collaboration, longitudinal collection, and varied protocol needs.
Evidence and scope
The responsibilities and dates above come from Kevin’s career documents. They establish his contribution to the program; they do not imply authorship of every XLH publication or ownership of the medical conclusions. Public author-credit evidence in this archive is strongest for the separate LC-FAOD disease-monitoring abstract, which is identified separately.
Sources and record basis
The project account is based on Kevin’s CV, approved career statements, and supporting project materials. Related public research and professional work are available in the source index.
This record documents longitudinal XLH research and patient/site collaboration. It does not establish Dexcom CGM integration or use within BEYONDXLH. The separate Dexcom record describes the supported sensor-integration work. The BEYONDXLH record documents XLH research; it does not establish Dexcom CGM use in that program.